Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

Por Comen, E., Davids, M., Kirchhoff, T., Hudis, C., Offit, K., Robson, M.
Publicado em 2011

Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women

Por Comen, E., Balistreri, L., Gönen, M., Dutra-Clarke, A., Fazio, M., Vijai, J., Stadler, Z., Kauff, N., Kirchhoff, T., Hudis, C., Offit, K., Robson, M.
Publicado em 2010

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from...

Por Smyth, L. M., Iyengar, N. M., Chen, M. F., Popper, S. M., Patil, S, Wasserheit-Lieblich, C., Argolo, D. F., Singh, J. C., Chandarlapaty, S, Sugarman, S. M., Comen, E. A., Drullinsky, P. R., Traina, T. A., Troso-Sandoval, T, Baselga, J, Norton, L, Hudis, C. A., Dang, C. T.
Publicado no Breast Cancer Res Treat (2016)